ATE538798T1 - Zusammensetzungen und ihre verwendungen gegen niedermolekulare ptpase - Google Patents
Zusammensetzungen und ihre verwendungen gegen niedermolekulare ptpaseInfo
- Publication number
- ATE538798T1 ATE538798T1 AT06771192T AT06771192T ATE538798T1 AT E538798 T1 ATE538798 T1 AT E538798T1 AT 06771192 T AT06771192 T AT 06771192T AT 06771192 T AT06771192 T AT 06771192T AT E538798 T1 ATE538798 T1 AT E538798T1
- Authority
- AT
- Austria
- Prior art keywords
- ptpase
- compositions
- diabetes
- methods
- low molecular
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Means For Warming Up And Starting Carburetors (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68440005P | 2005-05-24 | 2005-05-24 | |
US74220705P | 2005-12-01 | 2005-12-01 | |
PCT/US2006/020272 WO2006127913A2 (en) | 2005-05-24 | 2006-05-24 | Modulation of lmw-ptpase expression |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE538798T1 true ATE538798T1 (de) | 2012-01-15 |
Family
ID=37452845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06771192T ATE538798T1 (de) | 2005-05-24 | 2006-05-24 | Zusammensetzungen und ihre verwendungen gegen niedermolekulare ptpase |
Country Status (7)
Country | Link |
---|---|
US (1) | US20090221671A1 (de) |
EP (2) | EP2462937A1 (de) |
JP (1) | JP2008541729A (de) |
AT (1) | ATE538798T1 (de) |
AU (1) | AU2006249925A1 (de) |
CA (1) | CA2609180A1 (de) |
WO (1) | WO2006127913A2 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8951981B2 (en) | 2009-06-16 | 2015-02-10 | Curna, Inc. | Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1 |
JP6031356B2 (ja) * | 2009-12-23 | 2016-11-24 | カッパーアールエヌエー,インコーポレイテッド | Ucp2に対する天然アンチセンス転写産物の阻害による脱共役タンパク質2(ucp2)関連疾患の治療 |
KR101853509B1 (ko) * | 2010-01-06 | 2018-04-30 | 큐알엔에이, 인크. | 췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료 |
WO2014172440A1 (en) * | 2013-04-16 | 2014-10-23 | Watlow Electric Manufacturing Company | Process controller with integrated optical sensing |
CR20180606A (es) | 2016-07-01 | 2019-02-14 | Hoffmann La Roche | Oligonucleótidos antisentido para modular la expresión de htra1 |
US20190055564A1 (en) * | 2017-06-01 | 2019-02-21 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides for modulating htra1 expression |
AU2018390167A1 (en) * | 2017-12-21 | 2020-06-11 | F. Hoffmann-La Roche Ag | Companion diagnostic for HTRA1 RNA antagonists |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
FR2692265B1 (fr) | 1992-05-25 | 1996-11-08 | Centre Nat Rech Scient | Composes biologiquement actifs de type phosphotriesters. |
FR2705099B1 (fr) | 1993-05-12 | 1995-08-04 | Centre Nat Rech Scient | Oligonucléotides phosphorothioates triesters et procédé de préparation. |
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
US6238921B1 (en) * | 1998-03-26 | 2001-05-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human mdm2 expression |
US20030228597A1 (en) * | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
US20040226056A1 (en) * | 1998-12-22 | 2004-11-11 | Myriad Genetics, Incorporated | Compositions and methods for treating neurological disorders and diseases |
US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
US20020055479A1 (en) * | 2000-01-18 | 2002-05-09 | Cowsert Lex M. | Antisense modulation of PTP1B expression |
US6423543B1 (en) * | 2000-12-20 | 2002-07-23 | Isis Pharmaceuticals, Inc. | Antisense modulation of hepsin expression |
US6869768B2 (en) * | 2001-09-07 | 2005-03-22 | City Of Hope | Association between the acid phosphatase (ACP1) gene and Alzheimer's disease |
WO2003038045A2 (en) * | 2001-10-29 | 2003-05-08 | City Of Hope | Acid phosphatase (acp1) gene as a susceptibility locus for hyperlipidemia |
WO2003099313A1 (en) * | 2002-05-23 | 2003-12-04 | Purdue Research Foundation | Low molecular weight protein tyrosine phosphatase (lmw-ptp) as a diagnostic and therapeutic target |
US20050164254A1 (en) * | 2002-06-14 | 2005-07-28 | Bennett C. F. | Compositions and their uses directed to metabolic proteins |
WO2004016749A2 (en) * | 2002-08-14 | 2004-02-26 | Pharmacia Corporation | Antisense modulation of acyl-coa synthetase 1 expression |
EP2305813A3 (de) * | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Funktionale und hyperfunktionale siRNA |
US20050147593A1 (en) * | 2003-05-22 | 2005-07-07 | Medimmune, Inc. | EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders |
JP4888065B2 (ja) * | 2005-12-08 | 2012-02-29 | オムロン株式会社 | レーザスキャン装置 |
-
2006
- 2006-05-24 EP EP11194974A patent/EP2462937A1/de not_active Ceased
- 2006-05-24 JP JP2008513714A patent/JP2008541729A/ja active Pending
- 2006-05-24 WO PCT/US2006/020272 patent/WO2006127913A2/en active Application Filing
- 2006-05-24 US US11/915,124 patent/US20090221671A1/en not_active Abandoned
- 2006-05-24 AU AU2006249925A patent/AU2006249925A1/en not_active Abandoned
- 2006-05-24 AT AT06771192T patent/ATE538798T1/de active
- 2006-05-24 CA CA002609180A patent/CA2609180A1/en not_active Abandoned
- 2006-05-24 EP EP06771192A patent/EP1888083B1/de not_active Not-in-force
Also Published As
Publication number | Publication date |
---|---|
AU2006249925A1 (en) | 2006-11-30 |
CA2609180A1 (en) | 2006-11-30 |
EP2462937A1 (de) | 2012-06-13 |
EP1888083A4 (de) | 2009-10-21 |
EP1888083B1 (de) | 2011-12-28 |
WO2006127913A3 (en) | 2007-04-12 |
US20090221671A1 (en) | 2009-09-03 |
JP2008541729A (ja) | 2008-11-27 |
EP1888083A2 (de) | 2008-02-20 |
WO2006127913A2 (en) | 2006-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE538798T1 (de) | Zusammensetzungen und ihre verwendungen gegen niedermolekulare ptpase | |
CY1121134T1 (el) | Συνθεσεις και μεθοδοι για την τροποποιηση της smn2 συγκολλησης | |
WO2007131232A3 (en) | Compositions and their uses directed to ptpr alpha | |
WO2007055950A3 (en) | Polycation-polyanion complexes, compositions and methods of use thereof | |
EA201170149A1 (ru) | Новые аналоги инсулина пролонгированной активности | |
ATE456369T1 (de) | Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen | |
MY176938A (en) | 3,5-disubstituted and 3,5,7-trisubstituted-3h-oxazolo and 3h-thiazolo[4,5-d] pyrimidin-2-one compounds and prodrugs thereof | |
EA200900741A1 (ru) | Способы лечения гиперхолестеринемии | |
EA200601746A1 (ru) | Применение ротиготина для лечения и предупреждения синдрома "паркинсонизм-плюс" | |
MY145590A (en) | Phenylacetamides and their use as glucokinase modulators | |
EA021275B9 (ru) | Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания | |
EA200800661A1 (ru) | Полимерные конъюгаты k-252а и его производных | |
ATE534378T1 (de) | Titrierung von tapentadol | |
EA200870254A1 (ru) | Способ лечения воспалительных заболеваний | |
CR9427A (es) | Combinacion terapeutica en casos de hiperplasia prostatica benigna | |
SE0401342D0 (sv) | Therapeutic compounds | |
DK2319517T3 (da) | Anvendelse af prodrugs til okulær, intravenøs administration | |
WO2006091841A3 (en) | Compositions and their uses directed to il-4r alpha | |
SE0401345D0 (sv) | Therapeutic compounds: Pyridine as scaffold | |
RS52825B (en) | PROCEDURES FOR THE TREATMENT OF DISORDERS OR DISEASES RELATED TO HYPERLIPIDEMIA AND HYPERHOLESTEROLEMIA WITH MINIMIZATION OF ADVERSE EFFECTS | |
DE602006001699D1 (de) | Stabile pharmazeutische Zusammensetzung mit Linezolid Form IV | |
MX2009003516A (es) | Formas de dosificacion solidas farmaceuticas que comprenden compuestos microincluidos en polimeros ionicos insolubles en agua. | |
WO2008063768A3 (en) | Compositions and methods for treating metabolic diseases | |
WO2006127976A3 (en) | Compositions and their uses directed to ptpru | |
WO2007025229A3 (en) | Compositions and their uses directed to hsp27 |